996 related articles for article (PubMed ID: 33154106)
41. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
42. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
Nat Commun; 2020 Sep; 11(1):4528. PubMed ID: 32913273
[TBL] [Abstract][Full Text] [Related]
43. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
44. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
[TBL] [Abstract][Full Text] [Related]
45. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
[TBL] [Abstract][Full Text] [Related]
46. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
[TBL] [Abstract][Full Text] [Related]
47. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
[TBL] [Abstract][Full Text] [Related]
48. Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
Khatri I; Staal FJT; van Dongen JJM
Front Immunol; 2020; 11():570018. PubMed ID: 33042151
[TBL] [Abstract][Full Text] [Related]
49. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
Chen X; Gentili M; Hacohen N; Regev A
Nat Commun; 2021 Sep; 12(1):5506. PubMed ID: 34535642
[TBL] [Abstract][Full Text] [Related]
50. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization.
Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X
J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467
[TBL] [Abstract][Full Text] [Related]
51. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
52. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Kim C; Ryu DK; Lee J; Kim YI; Seo JM; Kim YG; Jeong JH; Kim M; Kim JI; Kim P; Bae JS; Shim EY; Lee MS; Kim MS; Noh H; Park GS; Park JS; Son D; An Y; Lee JN; Kwon KS; Lee JY; Lee H; Yang JS; Kim KC; Kim SS; Woo HM; Kim JW; Park MS; Yu KM; Kim SM; Kim EH; Park SJ; Jeong ST; Yu CH; Song Y; Gu SH; Oh H; Koo BS; Hong JJ; Ryu CM; Park WB; Oh MD; Choi YK; Lee SY
Nat Commun; 2021 Jan; 12(1):288. PubMed ID: 33436577
[TBL] [Abstract][Full Text] [Related]
53. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
[TBL] [Abstract][Full Text] [Related]
54. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Liu Y; Soh WT; Kishikawa JI; Hirose M; Nakayama EE; Li S; Sasai M; Suzuki T; Tada A; Arakawa A; Matsuoka S; Akamatsu K; Matsuda M; Ono C; Torii S; Kishida K; Jin H; Nakai W; Arase N; Nakagawa A; Matsumoto M; Nakazaki Y; Shindo Y; Kohyama M; Tomii K; Ohmura K; Ohshima S; Okamoto T; Yamamoto M; Nakagami H; Matsuura Y; Nakagawa A; Kato T; Okada M; Standley DM; Shioda T; Arase H
Cell; 2021 Jun; 184(13):3452-3466.e18. PubMed ID: 34139176
[TBL] [Abstract][Full Text] [Related]
55. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
56. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
Noy-Porat T; Makdasi E; Alcalay R; Mechaly A; Levy Y; Bercovich-Kinori A; Zauberman A; Tamir H; Yahalom-Ronen Y; Israeli M; Epstein E; Achdout H; Melamed S; Chitlaru T; Weiss S; Peretz E; Rosen O; Paran N; Yitzhaki S; Shapira SC; Israely T; Mazor O; Rosenfeld R
Nat Commun; 2020 Aug; 11(1):4303. PubMed ID: 32855401
[TBL] [Abstract][Full Text] [Related]
57. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
58. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.
Zupancic JM; Desai AA; Schardt JS; Pornnoppadol G; Makowski EK; Smith MD; Kennedy AA; Garcia de Mattos Barbosa M; Cascalho M; Lanigan TM; Tai AW; Tessier PM
Cell Chem Biol; 2021 Sep; 28(9):1379-1388.e7. PubMed ID: 34171229
[TBL] [Abstract][Full Text] [Related]
59. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
[TBL] [Abstract][Full Text] [Related]
60. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
